Lately internet users have been talking about the D-dimer test. For those who don’t know what D-dimer is, it is a “fibrin degradation product”. According to a report published in news-medical.net, the D-dimer has been used to measure and evaluate clot formations in patients ’bodies. In the midst of the ongoing pandemic, patients present with elevated levels of D-dimers. Read on to find out what the normal range of D-dimer is?
What is the normal range of D-dimers?
Meaning of D-Dimer
The news-medical.net report states that the liver is responsible for producing important proteins involved in the clotting process, one of these proteins is fibrinogen. A fibrinogen molecule is made up of three pairs of polypeptide chains, which is a linear chain of amino acids.
How does dimer D relate to COVID-19?
For research purposes, D-dimer levels were tested in several patients hospitalized with COVID-19. It was done to determine if a biomarker such as the D dimer could help predict patient outcome in relation to COVID-19. A normal range of D dimers is less than 0.50. A positive D-Dimer range is 0.50 or higher. According to a study in ncbi.nlm.nih.gov called “Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis,” published in the Journal de Medicine Vasculaire, Of the total of 274 patients, the 113 who did not survive were found to have higher D-dimer levels at a median of 4.6 µg / mL. Of the remaining 161 surviving patients, D-dimer levels had averaged 0.6 µg / ml.
The said study was conducted in China. More research needs are made in this area. The study further mentioned that patients with severe COVID-19 have a higher level of dimer D than those with non-severe disease. A D dimer greater than 0.5 μg / ml is associated with severe infection in patients with COVID-19.
What roles do biomarkers play in the identification of COVID-19?
The news-medical.net report mentioned that it is estimated that 10-15% of patients with COVID-19 will experience critical forms of these diseases. They are likely to progress to severe pneumonia, hypoxia, and even respiratory failure. Approximately 5% of these severe cases of COVID-19 tend to decrease further to acute respiratory disorder syndrome (ARDS) or even to multiple organ failure (MOF). To improve the early identification of COVID-19, in order to lessen the damage the virus can cause to our bodies, many researchers are trying to identify reliable biomarkers.